Life Saving Drugs Program – Eliglustat (Cerdelga®) outcome statement

This document states the outcome of Sanofi-Aventis Australia's application to include eliglustat on the Life Saving Drugs Program.


Life Saving Drugs Program – Eliglustat (Cerdelga®) outcome statement

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Date last updated:
Publication type:
General public

The Life Saving Drugs Program Expert Panel considered this application from Sanofi-Aventis Australia Pty Ltd on 15 November 2019. They deferred their decision until the Government-agreed outcomes from the Gaucher disease LSDP medicines review were known. 

Help us improve

If you would like a response please use the enquiries form instead.